| SIM0010-5MG
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar)
| 5 mg
| BioXCell
| Blocking of PD-1/PD-L signaling, Functional assays
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0024-100MG
| InVivoSIM anti-human integrin ?4?7 (LPAM-1) (Vedolizumab Biosimilar)
| 100 mg
| BioXCell
| Functional assays, ELISA, Western blot,
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0028-100MG
| InVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar)
| 100 mg
| BioXCell
| Functional assays, Flow Cytometry,
|
| Human
| Human
| Request Quotation
| Request
|
| CP174-100MG
| RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
| 100 mg
| BioXCell
|
|
| Human
|
| Request Quotation
| Request
|
| SIM0027-5MG
| InVivoSIM anti-human PD-L1 (Durvalumab Biosimilar)
| 5 mg
| BioXCell
| ELISA, Flow Cytometry, Western Blot, Functional as
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0030-5MG
| InVivoSIM anti-human IL-6 (Siltuximab Biosimilar)
| 5 mg
| BioXCell
| Functional assays, ELISA,
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0013-50MG
| InVivoSIM anti-human IL-17A (Secukinumab Biosimilar)
| 50 mg
| BioXCell
| Functional assays, ELISA, Immunofluoresence, Immun
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0016-1MG
| InVivoSIM anti-human IgE (Omalizumab Biosimilar)
| 1 mg
| BioXCell
| IgE neutralization
, , Flow cytometry
, , ELISA
|
| Human
| Human
| Request Quotation
| Request
|
| CP131-100MG
| RecombiMAb anti-mouse CSF1R (CD115)
| 100 mg
| BioXCell
| in vivo macrophage depletion*, in vitro CSF1R neut
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| RT0267-5MG
| ReadyTag anti-OVA
| 5 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| SIM0028-1MG
| InVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar)
| 1 mg
| BioXCell
| Functional assays, Flow Cytometry,
|
| Human
| Human
| Request Quotation
| Request
|
| CP173-100MG
| RecombiMAb human IgG1 (D265A) isotype control, anti-hen egg lysozyme
| 100 mg
| BioXCell
|
|
| Human
|
| Request Quotation
| Request
|
| CP014-1MG
| RecombiMAb anti-mouse LAG-3
| 1 mg
| BioXCell
| in vivo LAG-3 neutralization*, in vitro LAG-3 neut
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| SIM0021-25MG
| InVivoSIM anti-human PD-L1 (Avelumab Biosimilar)
| 25 mg
| BioXCell
| Functional assays, ELISA, in vitro PD-L1 blockade
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0024-50MG
| InVivoSIM anti-human integrin ?4?7 (LPAM-1) (Vedolizumab Biosimilar)
| 50 mg
| BioXCell
| Functional assays, ELISA, Western blot,
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0023-25MG
| InVivoSIM anti-human IL-4R? (CD124) (Dupilumab Biosimilar)
| 25 mg
| BioXCell
| Functional assays,
|
| Human
| Human
| Request Quotation
| Request
|
| CP156-50MG
| RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity
| 50 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| SIM0017-25MG
| InVivoSIM anti-human NGF (Tanezumab Biosimilar)
| 25 mg
| BioXCell
| NGF neutralization
, , ELISA
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0023-1MG
| InVivoSIM anti-human IL-4R? (CD124) (Dupilumab Biosimilar)
| 1 mg
| BioXCell
| Functional assays,
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0020-1MG
| InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar)
| 1 mg
| BioXCell
| Functional assays,
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0029-1MG
| InVivoSIM anti-human IL-17A (Ixekizumab Biosimilar)
| 1 mg
| BioXCell
| Functional assays, ELISA, Immunofluorescence, Flow
|
| Human
| Human
| Request Quotation
| Request
|
| SIM0018-5MG
| InVivoSIM anti-human integrin ?4?1 (VLA-4)
| 5 mg
| BioXCell
| Functional assays
, Flow cytometry
|
|
|
| Request Quotation
| Request
|
| SIM0013-25MG
| InVivoSIM anti-human IL-17A (Secukinumab Biosimilar)
| 25 mg
| BioXCell
| Functional assays, ELISA, Immunofluoresence, Immun
|
| Human
| Human
| Request Quotation
| Request
|
| CP038-1MG
| RecombiMAb anti-mouse 4-1BB (CD137) (LALA-PG)
| 1 mg
| BioXCell
| in vivo activation of 4-1BB*, *Reported for the or
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| CP146-50MG
| RecombiMAb anti-mouse CTLA-4 (CD152)
| 50 mg
| BioXCell
| in vivo CTLA-4 neutralization*, in vitro CTLA-4 ne
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0366-50MG
| InVivoPlus mouse IgG2c isotype control, anti-dengue virus
| 50 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| CP040-1MG
| RecombiMAb anti-mouse 4-1BBL (CD137L)
| 1 mg
| BioXCell
| in vivo 4-1BBL blockade*, ELISA*, *Reported for th
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| CP131-50MG
| RecombiMAb anti-mouse CSF1R (CD115)
| 50 mg
| BioXCell
| in vivo macrophage depletion*, in vitro CSF1R neut
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| CP150-25MG
| RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme
| 25 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| CP154-5MG
| RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG)
| 5 mg
| BioXCell
| in vivo PD-L1 blockade*, Immunofluorescence*, Immu
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| SIM0030-100MG
| InVivoSIM anti-human IL-6 (Siltuximab Biosimilar)
| 100 mg
| BioXCell
| Functional assays, ELISA,
|
| Human
| Human
| Request Quotation
| Request
|
| CP151-50MG
| RecombiMAb anti-mouse PD-1 (CD279) (D265A)
| 50 mg
| BioXCell
| in vivo blocking of PD-1/PD-L signaling*, *Reporte
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| CP150-50MG
| RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme
| 50 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|